[논문]Predictors of Urinary Morbidity in Cs-131 Prostate Brachytherapy Implants

Smith, R.P.; Jones, H.A.; Beriwal, S.; Gokhale, A.; Benoit, R.

doi:10.1016/j.ijrobp.2010.06.017

Predictors of Urinary Morbidity in Cs-131 Prostate Brachytherapy Implants

International journal of radiation oncology, biology, physics, v.81 no.3, 2011년, pp.745 - 750

Smith, R.P. (Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania) , Jones, H.A. , Beriwal, S. , Gokhale, A. , Benoit, R.

Abstract ▼ AI-Helper

Purpose: Cesium-131 is a newer radioisotope being used in prostate brachytherapy (PB). This study was conducted to determine the predictors of urinary morbidity with Cs-131 PB. Methods and Materials: A cohort of 159 patients underwent PB with Cs-131 at our institution and were followed by using Expanded Prostate Cancer Index Composite (EPIC) surveys to determine urinary morbidity over time. EPIC scores were obtained preoperatively and postoperatively at 2 and 4 weeks, and 3 and 6 months. Different factors were evaluated to determine their individual effect on urinary morbidity, including patient characteristics, disease characteristics, treatment, and dosimetry. Multivariate analysis of covariance was carried out to identify baseline determinants affecting urinary morbidity. Factors contributing to the need for postoperative catheterization were also studied and reported. Results: At 2 weeks, patient age, dose to 90% of the organ (D90), bladder neck maximum dose (Dmax), and external beam radiation therapy (EBRT) predicted for worse function. At 4 weeks, age and EBRT continued to predict for worse function. At the 3-month mark, better preoperative urinary function, preoperative alpha blockers, bladder neck Dmax, and EBRT predicted for worse urinary morbidity. At 6 months, better preoperative urinary function, preoperative alpha blockers, bladder neck Dmax, and EBRT were predictive of increased urinary problems. High bladder neck Dmax and poor preoperative urinary function predicted for the need for catheterization. Conclusions: The use of EBRT plus Cs-131 PB predicts for worse urinary toxicity at all time points studied. Patients should be cautioned about this. Age was a consistent predictor of worsened morbidity immediately following Cs-131 PB, while bladder Dmax was the only consistent dosimetric predictor. Paradoxically, patients with better preoperative urinary function had worse urinary morbidity at 3 and 6 months, consistent with recently published literature.

주제어

참고문헌 (33)

Int J Radiat Oncol Biol Phys Grimm 51 31 2001 10.1016/S0360-3016(01)01601-7 10-year biochemical (prostate-specific antigen) control of prostate cancer with I-125 brachytherapy

상세보기
Int J Radiat Oncol Biol Phys Kollmeier 57 645 2003 10.1016/S0360-3016(03)00627-8 Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: Importance of patient selection and implant quality

상세보기
J Urol Potters 173 1562 2005 10.1097/01.ju.0000154633.73092.8e 12-year outcomes following permanent prostate brachytherapy in patients with classically localized prostate cancer

상세보기
Urology Anderson 74 601 2009 10.1016/j.urology.2009.04.060 Urinary side effects and complications after permanent prostate brachytherapy: The M.D. Anderson Cancer Center experience

상세보기
Int J Radiat Oncol Biol Phys Keyes 73 1023 2009 10.1016/j.ijrobp.2008.05.022 Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients

상세보기
Int J Radiat Oncol Biol Phys Van Gellekom 63 772 2005 10.1016/j.ijrobp.2005.03.046 Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry

상세보기
J Clin Oncol Talcott 21 3979 2003 10.1200/JCO.2003.01.199 Time course and predictors of symptoms after primary prostate cancer therapy

상세보기
10.1016/j.urology.2009.12.084 Jacobs BL, Smith RP, Beriwal S, Benoit RM. Acute lower urinary tract symptoms after prostate brachytherapy with Cesium-131. Urology. Urology 2010, June 3 [epub ahead of print].

상세보기
Urology Wei 56 899 2000 10.1016/S0090-4295(00)00858-X Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer

상세보기
IsoRay Medical Inc. CS-131 product information sheet. Available at: http://www.isoray.com/.
Kinsey RR. The NuDat program for nuclear data on the web. National Nuclear Data Center, Brookhaven National Laboratory. Available at: http://www.nndc.bnl.gov/nndc/nudat/.
Med Phys Nath 22 209 1995 10.1118/1.597458 Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43

상세보기
J Clin Oncol Talcott 16 275 1998 10.1200/JCO.1998.16.1.275 Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study

상세보기
Int J Radiat Oncol Biol Phys Merrick 47 121 2000 10.1016/S0360-3016(99)00525-8 Temporal resolution of urinary morbidity following prostate brachytherapy

상세보기
Brachytherapy Neill 6 173 2007 10.1016/j.brachy.2007.03.003 The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry

상세보기
Urology Stone 69 338 2007 10.1016/j.urology.2006.10.001 Long-term urinary, sexual, and rectal morbidity in patients treated with I-125 prostate brachytherapy followed up for a minimum of 5 years

상세보기
J Urol Crook 179 141 2008 10.1016/j.juro.2007.08.136 Long-term urinary sequelae following 125iodine prostate brachytherapy

상세보기
Int J Radiat Oncol Biol Phys Niehaus 64 136 2006 10.1016/j.ijrobp.2005.06.035 The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy

상세보기
Int J Radiat Oncol Biol Phys Allen 62 981 2005 10.1016/j.ijrobp.2004.12.068 Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity

상세보기
Clin Oncol (R Coll Radiol) Kelly 18 326 2006 10.1016/j.clon.2006.02.007 Prediction of urinary symptoms after 125iodine prostate brachytherapy

상세보기
Int J Radiat Oncol Biol Phys Brown 47 353 2000 10.1016/S0360-3016(00)00433-8 Urinary morbidity with a modified peripheral loading technique of transperineal (125)I prostate implantation

상세보기
Int J Radiat Oncol Biol Phys Wallner 32 465 1995 10.1016/0360-3016(94)00599-G Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy

상세보기
Int J Radiat Oncol Biol Phys Merrick 56 454 2003 10.1016/S0360-3016(02)04600-X Long-term urinary quality of life following permanent prostate brachytherapy

상세보기
N Engl J Med Sanda 358 1250 2008 10.1056/NEJMoa074311 Quality of life and satisfaction with outcome among prostate-cancer survivors

상세보기
Int J Radiat Oncol Biol Phys Stock 66 389 2006 10.1016/j.ijrobp.2006.05.072 Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control

상세보기
Cancer Ragde 89 135 2000 10.1002/1097-0142(20000701)89:1<135::AID-CNCR18>3.0.CO;2-# Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up

상세보기
Brachytherapy Frank 6 2 2007 10.1016/j.brachy.2006.09.004 Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: A survey of practice patterns in the United States

상세보기
Int J Radiat Oncol Biol Phys Gelblum 45 59 1999 10.1016/S0360-3016(99)00176-5 Urinary morbidity following ultrasound-guided transperineal prostate seed implantation

상세보기
BJU Int Henderson 93 890 2004 10.1111/j.1464-410X.2004.4737h.x Urinary morbidity after 125I brachytherapy of the prostate

상세보기
Int J Radiat Oncol Biol Phys Locke 52 712 2002 10.1016/S0360-3016(01)02657-8 Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: A prospective study

상세보기
J Urol Terk 160 1379 1998 10.1016/S0022-5347(01)62542-4 Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate

상세보기
Int J Radiat Oncol Biol Phys Thomas 72 447 2008 10.1016/j.ijrobp.2007.12.052 Segmental urethral dosimetry and urinary toxicity in patients with no urinary symptoms prior to permanent prostate brachytherapy

상세보기
J Clin Oncol Chen 27 24 3916 2009 10.1200/JCO.2008.18.6486 Individualizing quality-of-life outcomes reporting: How localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function

상세보기

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증

Predictors of Urinary Morbidity in Cs-131 Prostate Brachytherapy Implants

Abstract ▼ AI-Helper

주제어

참고문헌 (33)

이 논문을 인용한 문헌

관련 콘텐츠

이 논문과 함께 이용한 콘텐츠

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트